Core Scientific’s top investor pushes back on $9B CoreWeave deal

Two Seas Capital, Core Scientific’s largest shareholder, is opposing the $9 billion all-stock takeover by AI cloud firm CoreWeave, calling the valuation “inadequate” and the deal structure risky. The firm, holding 6.3% of shares, argues the terms favor CoreWeave while leaving Core Scientific investors exposed to share price volatility. It urges fellow shareholders to reject the proposal, citing a sharp post-announcement stock decline.